Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib plus nab-paclitaxel in biomarker-selected advanced triple-negative breast cancer
MOH_2020-03-24_008784Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alpelisib and paclitaxel in triple-negative breast cancer (TNBC) and breast cancer (5 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started Mar 2020; status: active, not recruiting.
02
Drugs
alpelisibpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on MOH_2020-03-24_008784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-24_008784.